These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 32376001

  • 1. Comparison of Nafcillin and Cefazolin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia.
    Twilla JD, Algrim A, Adams EH, Samarin M, Cummings C, Finch CK.
    Am J Med Sci; 2020 Jul; 360(1):35-41. PubMed ID: 32376001
    [Abstract] [Full Text] [Related]

  • 2. Does the Beta-Lactam Matter? Nafcillin versus Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections.
    Burrelli CC, Broadbent EK, Margulis A, Snyder GM, Gold HS, McCoy C, Mahoney MV, Hirsch EB.
    Chemotherapy; 2018 Jul; 63(6):345-351. PubMed ID: 30965335
    [Abstract] [Full Text] [Related]

  • 3. Cefazolin versus Nafcillin for Methicillin-Sensitive Staphylococcus aureus Bloodstream Infection in a California Tertiary Medical Center.
    Pollett S, Baxi SM, Rutherford GW, Doernberg SB, Bacchetti P, Chambers HF.
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4684-9. PubMed ID: 27216053
    [Abstract] [Full Text] [Related]

  • 4. A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bloodstream infections.
    Miller MA, Fish DN, Barber GR, Barron MA, Goolsby TA, Moine P, Mueller SW.
    J Microbiol Immunol Infect; 2020 Apr; 53(2):321-327. PubMed ID: 30190234
    [Abstract] [Full Text] [Related]

  • 5. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia.
    Schweizer ML, Furuno JP, Harris AD, Johnson JK, Shardell MD, McGregor JC, Thom KA, Cosgrove SE, Sakoulas G, Perencevich EN.
    BMC Infect Dis; 2011 Oct 19; 11():279. PubMed ID: 22011388
    [Abstract] [Full Text] [Related]

  • 6. Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia?
    Lee S, Choe PG, Song KH, Park SW, Kim HB, Kim NJ, Kim EC, Park WB, Oh MD.
    Antimicrob Agents Chemother; 2011 Nov 19; 55(11):5122-6. PubMed ID: 21825299
    [Abstract] [Full Text] [Related]

  • 7. Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective multicentre cohort study in Korea.
    Lee S, Song KH, Jung SI, Park WB, Lee SH, Kim YS, Kwak YG, Kim YK, Kiem SM, Kim HI, Kim ES, Park KH, Kim NJ, Jang HC, Kim HB, Korea INfectious Diseases (KIND) study group.
    Clin Microbiol Infect; 2018 Feb 19; 24(2):152-158. PubMed ID: 28694202
    [Abstract] [Full Text] [Related]

  • 8. Comparative Effectiveness of Cefazolin Versus Nafcillin or Oxacillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Infections Complicated by Bacteremia: A Nationwide Cohort Study.
    McDanel JS, Roghmann MC, Perencevich EN, Ohl ME, Goto M, Livorsi DJ, Jones M, Albertson JP, Nair R, O'Shea AMJ, Schweizer ML.
    Clin Infect Dis; 2017 Jul 01; 65(1):100-106. PubMed ID: 28379314
    [Abstract] [Full Text] [Related]

  • 9. Nafcillin versus cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia.
    Monogue ML, Ortwine JK, Wei W, Eljaaly K, Bhavan KP.
    J Infect Public Health; 2018 Jul 01; 11(5):727-731. PubMed ID: 29526442
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study.
    Oh DH, Kim JJ, Kim J, Seong H, Lee SJ, Kim YC, Kim EJ, Jung IY, Jeong WY, Jeong SJ, Ku NS, Han SH, Choi JY, Song YG, Kim JM.
    BMC Infect Dis; 2018 Jan 30; 18(1):60. PubMed ID: 29378565
    [Abstract] [Full Text] [Related]

  • 11. Retrospective Analysis of Adverse Drug Events Between Nafcillin Versus Cefazolin for Treatment of Methicillin-Susceptible Staphylococcus aureus Infections.
    Chan L, Chan-Tompkins NH, Como J, Guarascio AJ.
    Ann Pharmacother; 2020 Jul 30; 54(7):662-668. PubMed ID: 31888347
    [Abstract] [Full Text] [Related]

  • 12. β-Lactam Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Comparative Review of Cefazolin versus Antistaphylococcal Penicillins.
    Li J, Echevarria KL, Traugott KA.
    Pharmacotherapy; 2017 Mar 30; 37(3):346-360. PubMed ID: 28035690
    [Abstract] [Full Text] [Related]

  • 13. Clinical implications of cefazolin inoculum effect and β-lactamase type on methicillin-susceptible Staphylococcus aureus bacteremia.
    Lee S, Kwon KT, Kim HI, Chang HH, Lee JM, Choe PG, Park WB, Kim NJ, Oh MD, Song DY, Kim SW.
    Microb Drug Resist; 2014 Dec 30; 20(6):568-74. PubMed ID: 25000230
    [Abstract] [Full Text] [Related]

  • 14. Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting.
    Youngster I, Shenoy ES, Hooper DC, Nelson SB.
    Clin Infect Dis; 2014 Aug 01; 59(3):369-75. PubMed ID: 24785233
    [Abstract] [Full Text] [Related]

  • 15. Methicillin-Susceptible Staphylococcus Aureus Bacteremia: Cefazolin in Prime But Nafcillin Not Ready for an Exit.
    Sarria JC.
    Am J Med Sci; 2020 Jul 01; 360(1):3-4. PubMed ID: 32439151
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus.
    Li J, Echevarria KL, Hughes DW, Cadena JA, Bowling JE, Lewis JS.
    Antimicrob Agents Chemother; 2014 Sep 01; 58(9):5117-24. PubMed ID: 24936596
    [Abstract] [Full Text] [Related]

  • 17. Meta-analysis of trials comparing cefazolin to antistaphylococcal penicillins in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia.
    Rindone JP, Mellen CK.
    Br J Clin Pharmacol; 2018 Jun 01; 84(6):1258-1266. PubMed ID: 29600576
    [Abstract] [Full Text] [Related]

  • 18. Tolerability of Cefazolin in Nafcillin-Intolerant Patients for the Treatment of Methicillin-Susceptible Staphylococcus aureus Infections.
    Gandhi AM, Shah MD, Donohue LE, Cox HL, Eby JC.
    Clin Infect Dis; 2021 Nov 02; 73(9):1650-1655. PubMed ID: 33905485
    [Abstract] [Full Text] [Related]

  • 19. Post-treatment outcomes of ceftriaxone versus antistaphylococcal penicillins or cefazolin for definitive therapy of methicillin-susceptible Staphylococcus aureus bacteremia.
    Yetmar ZA, Khodadadi RB, Go JR, Chesdachai S, Abu Saleh OM.
    Eur J Clin Microbiol Infect Dis; 2023 Apr 02; 42(4):423-430. PubMed ID: 36800065
    [Abstract] [Full Text] [Related]

  • 20. Implementation of a cefazolin-based stewardship pathway for methicillin-susceptible Staphylococcus aureus bloodstream infections paired with infectious diseases consultation.
    Lee BJ, Rao SN, Wang SK, Lee JY, Lakada IY, Gilbert EM, Barr VO, Postelnick MJ, Sutton SH, Zembower TR, Bolon M, Scheetz MH, Rhodes NJ.
    Int J Antimicrob Agents; 2017 May 02; 49(5):650-654. PubMed ID: 28279787
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.